GLP-1(32-36)amide

发表于由

GLP-1(32-36)amide; 纯度: 98.43%

GLP-1(32-36)amide，一种衍生自糖调节激素 GLP-1 的 C 末端的五肽。GLP-1(32-36)amide 可抑制糖尿病小鼠的体重增加并调节全身葡萄糖代谢。

GLP-1(32-36)amideamp;;

GLP-1(32-36)amide Chemical Structure

CAS No. : 1417302-71-6

规格 价格 是否有货 数量
5 mg ￥2750 In-stock
10 mg ￥4650 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

GLP-1(32-36)amide 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • GPCR/G Protein Compound Library
  • Diabetes Related Compound Library
  • Peptide Library

生物活性

GLP-1(32-36)amide, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice[1][2].

体外研究
(In Vitro)

GLP-1(32-36)amide (0.1-10 μM; 24 h) retains cell viability and decreases apoptosis against Streptozotocin (STZ; 1 μM) in INS‐1 cells[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[2]

Cell Line: INS‐1 cells
Concentration: 0.1, 1, 10 μM
Incubation Time: 24 hours
Result: Decreased cell viability only approximately 30% in 0.1 μM and approximately 20% in ≥1 μM while approximately 45% in saline-treated controls.

体内研究
(In Vivo)

GLP-1(32-36)amide (1 μmol/kg; i.p. once daily for 21 d) protects islet from damage, inhibits weight gain, and relieves symptoms of polydipsia in diabetic mice[2].
GLP-1(32-36)amide (1 μmol/kg; a single i.p.) slightly reduces the mean glucose lever at 30 min after the challenge of glucose in normal mice[2].
GLP-1(32-36)amide (50-70 nmol/kg/d; infusion for 12-16 weeks) prevents the development of diet-induced obesity and hepatic steatosis in high fat-fed mice[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male KM mice (6-8 weeks; 18-22 g) injected with STZ[2]
Dosage: 1 μmol/kg
Administration: I.p. once daily for 21 days
Result: Significantly lowered the cumulative values of food and water intake.
Lowered fasting glucose.
Reduced the level of Hemoglobin A1c (HbA1c).
Improved glucose tolerance.
Suppressed body weight gain.

分子量

570.73

Formula

C25H50N10O5
CAS 号

1417302-71-6
Sequence

Leu-Val-Lys-Gly-Arg-NH2
Sequence Shortening

LVKGR-NH2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -80deg;C 2 years
-20deg;C 1 year
In solvent -80deg;C 6 months
-20deg;C 1 month
溶解性数据
In Vitro:;

DMSO : 250 mg/mL (438.04 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.7521 mL 8.7607 mL 17.5214 mL
5 mM 0.3504 mL 1.7521 mL 3.5043 mL
10 mM 0.1752 mL 0.8761 mL 1.7521 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂：;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: ≥ 2.08 mg/mL (3.64 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.64 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂：;10% DMSO ;; 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (3.64 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.64 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂：;10% DMSO ;; 90% corn oil

    Solubility: ≥ 2.08 mg/mL (3.64 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.64 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献

  • [1]. Elahi D, et, al. GLP-1(32-36)amide, a novel pentapeptide cleavage product of GLP-1, modulates whole body glucose metabolism in dogs. Peptides. 2014 Sep;59:20-4.

    [2]. Sun L, et, al. Novel Pentapeptide GLP-1 (32-36) Amide Inhibits β-Cell Apoptosis In Vitro and Improves Glucose Disposal in Streptozotocin-Induced Diabetic Mice. Chem Biol Drug Des. 2015 Dec;86(6):1482-90.

    [3]. Tomas E, et, al. GLP-1(32-36)amide Pentapeptide Increases Basal Energy Expenditure and Inhibits Weight Gain in Obese Mice. Diabetes. 2015 Jul;64(7):2409-19.